CD154 is a negative regulator of autoaggressive CD8+ T cells in type 1 diabetes
AUTOR(ES)
McGregor, Catrin M.
FONTE
National Academy of Sciences
RESUMO
TNF/CD80 mice, a CD8+ T cell-mediated model for type 1 diabetes, transgenically express tumor necrosis factor α (TNF-α) and the costimulatory molecule CD80 in their pancreatic islets. Here we show that these molecules bypass the need for CD40–CD154 costimulatory interactions in activation of CD8+ T cells, allowing us to determine the role of CD40–CD154 signals in regulation of autoaggressive CD8+ T cells after their in vivo priming. TNF/CD80 CD154-deficient mice rapidly develop diabetes, whereas CD154-sufficient mice do not. This finding correlates with the decreased numbers of CD4+CD25+ T regulatory (TR) cells in the islets and pancreatic lymph nodes, in comparison to disease-protected CD154-sufficient mice. Administration of a CD40 agonistic antibody induces a systemic and tissue-specific increase in TR cells. However, this increase fails to delay diabetes development in the absence of CD154. Adoptive transfer studies show that CD8+ T cells from TNF/CD80 CD154-deficient, but not CD154-sufficient, mice are resistant to regulation in vivo. This study provides evidence that CD40-transduced signals initiate TR cell increase in vivo and that CD154-transduced signals sensitize autoaggressive CD8+ T cells to suppression.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=438979Documentos Relacionados
- CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-β–TGF-β receptor interactions in type 1 diabetes
- CD28 and inducible costimulator (ICOS) signalling can sustain CD154 expression on activated T cells
- Qa-1 restriction of CD8+ suppressor T cells
- Type 17 CD8+ T cells display enhanced antitumor immunity
- Sulfated beef insulin treatment elicits CD8+ T cells that may abrogate immunologic insulin resistance in type I diabetes.
